Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current ...
A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...
The first ever injectable drug that can prevent HIV has been approved for use in England and Wales. The drug, cabotegravir, would benefit an estimated 1,000 people at risk of HIV in England and Wales.
Daily Maverick on MSN
The long shot: Building behavioural science into HIV prevention
Lenacapavir (LEN) has arrived in South Africa, and this injectable form of pre-exposure prophylaxis (PrEP) marks a major ...
The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo. Phase 3 trials showed that ...
NEW ORLEANS -- A collaborative drug therapy management (CDTM) program introduced by pharmacists helped improve access to long-acting HIV prevention in at-risk individuals, a researcher reported here.
A nurse at Tudor Sub-County Hospital in Mombasa administers Lenacapavir injection during the rollout of the vaccine on March 13, 2026. [Robert Menza, Standard] Mombasa County has officially rolled out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results